Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 1998Journal of Clinical Oncology

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPeter McLaughlinHeidelberg UniversityAGA.J. Grillo-LópezThe University of Texas MD Anderson Cancer CenterBLBrian K. LinkUniversity of Iowa

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

McLaughlin et al. (1998) studied this question.

synapsesocial.com/papers/6a0da59bcae7912d2fa5268ahttps://doi.org/10.1200/jco.1998.16.8.2825
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia1992 · 177 citations
  2. 2Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.1990 · 188 citations
  3. 3Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation1984 · 695 citations